Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wolfram Mueller is active.

Publication


Featured researches published by Wolfram Mueller.


International Journal of Cancer | 1996

Prognostic value of E‐cadherin expression in 413 gastric carcinomas

Helmut E. Gabbert; Wolfram Mueller; Anke Schneiders; S. Meier; Roland Moll; Walter Birchmeier; Gerd Hommel

E‐cadherin is Ca2+‐dependent intercellular adhesion molecule known to exert an invasion‐suppressor function. In the present study, E‐cadherin expression was immunohistochemically investigated in a retrospective series of 413 RO‐resected gastric carcinomas using the monoclonal antibody (MAb) 5H9. Of these cases, 108 tumors revealed a preserved E‐cadherin expression similar to that of normal gastric mucosa. In 95 tumors, E‐cadherin expression was moderately reduced and in 86 tumors highly reduced. In 124 tumors, no or only a very weak dotted expression could be detected. There was a significant correlation between the degree of E‐cadherin expression and the grade of tumor differentiation, as well as with histological type according to the Laurén and the WHO classifications. In contrast, no correlation could be demonstrated between E‐cadherin expression and the prognostic parameters depth of invasion, lymph node involvement and vascular invasion. As shown by univariate Cox regression analysis, patients with E‐cadherin‐positive tumors had significantly better 3‐ and 5‐year survival rates than patients with E‐cadherin‐negative tumors. This prognostic impact remained present in a multivariate Cox regression analysis, including the prognostic parameters pT category, pN category and vascular invasion.


Clinical Cancer Research | 2005

EphB2 is a Prognostic Factor in Colorectal Cancer

Adrian M. Jubb; Fiona Zhong; Sheila Bheddah; Heike I. Grabsch; Gretchen Frantz; Wolfram Mueller; Vidya Kavi; Phil Quirke; Paul Polakis; Hartmut Koeppen

A receptor tyrosine kinase for ephrin ligands, EphB2 is expressed in colorectal cancer and has been proposed as a target for immunoconjugate therapy. The aim of this study was to perform a detailed histologic analysis of EphB2 expression in normal and neoplastic colorectal tissues. In addition, we sought to evaluate EphB2 expression as a prognostic factor in colorectal cancer. Expression of EphB2 was examined in normal colon (n = 28), colorectal cell lines (n = 20), colorectal adenomas (n = 148), primary cancers (n = 28), and metastases (n = 39) using immunohistochemistry. In addition, a series of primary cancers and matched normal (n = 342) with outcome data were profiled in tissue microarrays. The intensity of EphB2 expression was assessed in the entire series by immunohistochemistry, and in a subset by in situ hybridization. Overall survival and recurrence-free survival were correlated with EphB2 protein expression in retrospective subset analyses. Epithelial EphB2 expression was shown at all stages of colorectal tumorigenesis, including the base of all normal crypts, 77% of adenomas, 82% of primary cancers, and 64% of metastases. Although homogeneous expression was observed in adenomas, the pattern of staining was focal (mean 25%) in most malignant lesions. Patients whose tumor stained 2+ for EphB2 expression (versus 0/1+) exhibited significantly prolonged overall survival: mean duration of survival, 2,514 versus 1,044 days; hazard ratio, 0.45; 95% confidence interval, 0.18 to 0.95 (P = 0.035). In summary, EphB2 is expressed in normal crypts, colorectal adenomas, primary cancers, and metastases. High levels of EphB2 expression are associated with a longer mean duration of survival in colorectal cancer.


British Journal of Cancer | 2010

The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients

Nicholas P. West; Mit Dattani; P McShane; Gordon Hutchins; J Grabsch; Wolfram Mueller; Darren Treanor; P. Quirke; Heike I. Grabsch

Background:The proportion of epithelial and stromal cells in tumours is thought to have an important role in the progression of epithelial malignancy. We aimed to determine whether the relative proportion of tumour (PoT) was related to survival in colorectal cancer.Methods:The PoT at the luminal surface was measured by point counting using virtual tissue sections in a series of 145 colorectal cancer cases. The relationship of PoT to clinicopathological parameters including cancer-specific survival was analysed. Modified receiver operating characteristic curves were used to determine the optimum cut off points to dichotomise the data for survival analyses.Results:Tumours with PoT-low (⩽47%) were associated with significantly lower cancer-specific survival when compared to PoT-high (hazard ratio (HR)=2.087, 95% CI=1.088–4.003, P=0.024). On sub-analysis, the prognostic effect remained significant in colonic tumours (HR=2.474, 95% CI=1.132–5.408, P=0.019) and tumour, node, metastasis stage III disease (HR=3.480, 95% CI=0.325–9.136, P=0.007). Multivariate Cox regression analysis demonstrated that PoT was an independent prognostic marker when adjusted for age, T stage, N stage and extramural vascular invasion (P=0.017).Conclusion:This study suggests that a low proportion of tumour cells in colorectal cancer is related to poor cancer-specific survival. A relatively quick, inexpensive and well-established method such as point counting on diagnostic tissue sections could be used to identify a subset of patients who may benefit from adjuvant therapy.


Clinical Cancer Research | 2006

Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer

Heike I. Grabsch; Mit Dattani; Lisa Barker; Nicola Maughan; Karen Maude; Olaf Hansen; Helmut E. Gabbert; Phil Quirke; Wolfram Mueller

Purpose: The double-strand break (DSB) is the major DNA lesion leading to chromosomal aberrations and faithful repair is crucial for maintaining genomic instability. Very little is known about the expression of DNA DSB repair proteins in colorectal cancer. To address this issue, we examined the expression pattern of DSB repair key proteins ATM, BRCA1, BRCA2, Ku70, and Ku80 and their putative role in patients survival in a large series of colorectal cancer. Experimental Design: 342 sporadic colorectal cancer were subjected to immunohistochemistry by using specific antibodies for the various proteins investigated. Staining results were compared with clinicopathologic data, patient survival, as well as expression of mismatch repair proteins MLH1 and MSH2. Results: The expression pattern of both ATM and BRCA1 predicted survival in all colorectal cancer patients as well as in the small subgroup of patients that received adjuvant therapy. Low expression of ATM and BRCA1 was associated with loss of MLH1 or MSH2 expression. Conclusions: This is the first study to show a relationship between the expression of DNA DSB repair proteins ATM and BRCA1 and survival in colorectal cancer patients. Studies in tumors from large randomized trials are now necessary to validate our pilot data and establish the clinical usefulness of the immunohistochemical assay in predicting response to a particular adjuvant therapy regimen. Furthermore, our results indicate a possible link between expression of DNA mismatch repair and DNA DSB repair proteins in sporadic colorectal cancer, which warrants further investigation.


American Journal of Clinical Pathology | 2001

Chromosomal Imbalances in Gastric Cancer Correlation With Histologic Subtypes and Tumor Progression

Tsyoshi Noguchi; Hans-Christian Wirtz; Sonja Michaelis; Helmut E. Gabbert; Wolfram Mueller

DNA copy number changes were analyzed by comparative genomic hybridization (CGH) in 38 gastric carcinomas and correlated with tumor histologic type and progression. Gains of copy numbers were observed in all tumors, affecting all chromosomes except chromosome 16. The average number of copy number gains was 7 (range, 1-13), most frequently located on chromosomes 11, 12, 15, 17, and 20 in 45% to 97% of tumors. High-level amplifications were found on chromosomes 12, 15, 17, and 20; the latter was affected most frequently (66%). Loss of DNA copy numbers was detected in 14 tumors affecting 7 chromosomes. No statistically significant differences in the frequency and pattern of chromosomal imbalances were observed in tumor histologic type (Lauren classification) and grade of differentiation, as well as the prognostic parameters depth of invasion (pT) and lymph node involvement (pN). Our results indicate that in gastric cancer there is no specific recurrent pattern of DNA aberrations to be correlated with tumor histologic type or stage. However, CGH analysis could reveal new, recurrent genetic changes in gastric cancer affecting chromosomes sites that harbor genes known to participate in tumorigenesis and progression of several human malignant neoplasms.


Histopathology | 2001

Different patterns of beta-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome.

H Grabsch; S Takeno; Tsuyoshi Noguchi; G Hommel; Helmut E. Gabbert; Wolfram Mueller

Different patterns of β‐catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome


Gut | 2010

Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer

Elizabeth M. Tweedle; Ilyas Khattak; Chin Wee Ang; Taoufik Nedjadi; Rosalind E. Jenkins; B. Kevin Park; Helen Kalirai; Andy Dodson; Bahram Azadeh; Monica Terlizzo; Heike I. Grabsch; Wolfram Mueller; Sun Myint; Peter Clark; Helen Wong; William Greenhalf; John P. Neoptolemos; Paul Rooney; Eithne Costello

Objective There are currently no biomarkers in routine clinical use for determining prognosis in rectal cancer. In a preliminary proteomic study, variation in the levels of heat shock protein 27 (HSP27) in colorectal cancer samples was observed. The expression of HSP27 in a cohort of 404 patients with colorectal cancer with a predominantly poor prognosis was characterised and an investigation was undertaken of whether the differences were related to clinical outcome. HSP27 levels in diagnostic rectal biopsies were compared with matched surgical samples to determine whether changes in expression occurred in the time between biopsy and surgery and to investigate whether preoperative radiotherapy affected expression. Finally, the relationship between HSP27 expression and outcome was examined in an independent cohort of 315 patients with a predominantly good prognosis. Methods HSP27 levels were determined using combined two-dimensional gel electrophoresis and tandem mass spectrometry (12 cases) and by immunohistochemistry using tissue microarrays of colorectal cancers sampled at surgery and 80 diagnostic rectal biopsies. Results HSP27 overexpression was strongly associated with poor cancer-specific survival in rectal cancer (n=205, p=0.0063) but not colon cancer (n=199, p=0.7385) in the cohort with a poor prognosis. Multivariate Cox regression confirmed nodal metastases (p=0.0001) and HSP27 expression (p=0.0233) as independent markers of survival in rectal cancer. HSP27 levels remained unchanged in the majority of cases (65/80, 81%) between diagnostic biopsies and matched surgical samples, regardless of whether patients had undergone preoperative radiotherapy. In the cohort with a good prognosis the association between HSP27 and survival was not observed in patients with either rectal (n=115; p=0.308) or colon cancer (n=200; p=0.713). Conclusion In a large cohort of patients with a poor prognosis, HSP27 is an independent marker of poor outcome in rectal cancer; its expression is not altered by neoadjuvant radiotherapy. This finding requires validation in an independent similar cohort of patients with rectal cancer. HSP27 levels merit evaluation as a stratification factor for treatment of rectal cancer.


Annals of Surgical Oncology | 2002

DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity.

Tsuyoshi Noguchi; Tomotaka Shibata; Shoichi Fumoto; Yuzo Uchida; Wolfram Mueller; Shinsuke Takeno

BackgroundIt would be of considerable benefit to patients with esophageal cancer to be able to predict the effect of CRT before therapy, because critical side effects could be avoided and the therapeutic cost of CRT-resistant cases could be reduced. One of the biological parameters with the potential to indicate radioresponse is the DNA double-strand break repair enzyme DNA-PKcs. This study aims to clarify the correlation between DNA-PKcs expression and CRT effect.MethodsSixty-seven patients with progressive esophageal cancer treated with CRT were included in this study. The relationship between the expression of DNA-PKcs and the effect of CRT was examined by using immunohistochemistry. The relationships between DNA-PKcs expression, clinicopathologic parameters, and CRT effect were investigated statistically.ResultsA significant correlation was found between the expression of DNA-PKcs and the effect of CRT (P=.0149). The high-DNA-PKcs expression group showed greater therapeutic sensitivity than the low-expression croup. Clinicopathologic factors had no relationship with DNA-PKcs expression or CRT effect.ConclusionsThis study suggests that high expression of DNA-PKcs correlates with CRT effect. DNA-PKcs expression could, therefore, be useful for predicting the effect of CRT. In addition, these results may make it possible to plan therapy taking patients’ quality of life into consideration.


American Journal of Clinical Pathology | 2004

Prognostic Value of Cyclin B1 Protein Expression in Colorectal Cancer

Heike Grabsch; Kristina Lickvers; Olaf Hansen; Shinsuke Takeno; Reinhart Willers; Wolfgang Stock; Helmut E. Gabbert; Wolfram Mueller

We used immunohistochemical analysis to study the expression and prognostic impact of cyclin B1, a key molecule for G2-M phase transition during the cell cycle, in a series of 342 curatively resected colorectal carcinomas. In 269 tumors (78.7%), high expression of cyclin B1 in more than 10% of tumor cells was observed, but there was no association between cyclin B1 expression and histopathologic tumor features. Univariate analysis revealed no impact on disease-free and overall survival. Multivariate analysis revealed pT and pN categories, extramural blood vessel invasion, and low-grade tumor cell differentiation as independent prognostic predictors for overall survival, and pT and pN categories and tumor site for disease-free survival. According to our results, high expression of cyclin B1 is a frequent and early event in colorectal carcinomas. However, cyclin B1 expression is neither a predictor of prognosis in patients with colorectal cancer nor a suitable tool for identifying subgroups of patients at higher risk for disease recurrence.


Optical Engineering | 1992

Optical density of vascular tissue before and after 308-nm excimer laser irradiation

Hans-Joachim Schwarzmaier; Matthias P. Heintzen; Wolfram Mueller; Raimund Kaufmann; Myron L. Wolbarsht

Eleven autopsy specimens of healthy human abdominal aorta were irradiated under normal saline at room temperature (21.5±1.5°C) using an excimer laser (308 nm, 40 Hz, 115 ns, 57 mJ/mm2, 900-μm fused silica fiber). After irradiation, transmission spectra from untreated areas and from the damage zone next to the ablation area were obtained by microspectrophotometry (250- to 800-nm spectral range, 25-μm cryosections, 6.3-μm-diam measured area). The optical density (OD) of the damage zone was significantly increased over that of untreated areas in the near ultraviolet and parts of the visible spectral range. The OD of the irradiated tissue was higher, up to a factor of 2.4 for intima, a factor of 3.7 for media, and a factor of 2.3 for adventitia. At 308 nm, OD increased from 0.094±0.019 to 0.237±0.041 for intima (p<0.001), from 0.165±0.053 to 0.501±0.034 for media (p<0.001), and from 0.119±0.017 to 0.276±0.026 for adventitia (p<0.001). We show that excimer laser irradiation using a high repetition rate in combination with a high energy density changes significantly the optical properties of a human vessel wall.

Collaboration


Dive into the Wolfram Mueller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Heike Grabsch

St James's University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge